Oppenheimer Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Oppenheimer initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report published on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $48.00 price target on the stock.

A number of other equities analysts also recently commented on DNTH. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an overweight rating for the company. Wedbush lowered their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an outperform rating for the company in a research report on Friday, August 9th. Lifesci Capital raised Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Baird R W raised Dianthus Therapeutics to a strong-buy rating in a report on Friday, July 26th. Finally, HC Wainwright reiterated a buy rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Buy and an average target price of $45.13.

Dianthus Therapeutics Trading Up 2.0 %

Shares of NASDAQ DNTH opened at $28.00 on Thursday. The stock has a market cap of $821.77 million, a P/E ratio of -4.80 and a beta of 1.85. The business’s fifty day simple moving average is $27.87 and its 200-day simple moving average is $26.23. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. On average, equities analysts forecast that Dianthus Therapeutics will post -2.32 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $236,000. WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $265,000. Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $334,000. Finally, Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $390,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.